Cell therapy cryopreservation: more than storage
Read the interview to discover how a thoughtful cryopreservation strategy can help you reduce risk, support process consistency, and keep your cell therapy program moving forward.
As your cell therapy program moves toward clinical development, cryopreservation becomes about much more than storage. The choices you make can influence cell quality, process consistency, scalability, and readiness for the next stage of development. Focusing on viability alone may leave important risks and opportunities hidden until later.
In this interview, Iris Bischoff-Kont and Laura Aschmis discuss how you can build a cryopreservation strategy that supports reliable cell performance today while helping you prepare for future manufacturing and GMP requirements. You'll learn what to look for beyond viability and how to make decisions that support long-term development success.
Read the interview to explore:
- Why cryopreservation plays a critical role in cell quality, manufacturing consistency, and supply chain flexibility
- Why measuring viability alone may not give the full picture of post-thaw cell health and performance
- Which factors matter most when cryopreserving stem cells and other primary cell types
- How the right freezing medium can support scalability, regulatory readiness, and future commercialization
- What emerging approaches, including animal component-free and low-DMSO solutions, could mean for your workflow
- Practical considerations for building a cryopreservation strategy that grows with your program
This material was initially created by RegMedNet and the original version can be found here.